In addition, an association between hypercholesterolemia and increased apoB protein levels, together with the observation that reductions in apoB synthesis reduce LDLc and the incidence of atherosclerosis, has generated interest in apoB as a therapeutic target.55 Mipomersen (KYNAMRO®),39,40 an APOB-targeting antisense oligonucleotide, was approved by the FDA (the US Food and Drug Administration) for lowering LDL levels in patients with Homozygous Familiar Hypercholesterolemia. Here, APOB is linked to atherosclerosis.